Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA.
William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA; Department of Ophthalmology and Visual Sciences, The Ohio State University, Columbus, OH, USA.
J Control Release. 2023 Nov;363:464-483. doi: 10.1016/j.jconrel.2023.09.021. Epub 2023 Oct 4.
Several chronic eye diseases affect the posterior segment of the eye. Among them age-related macular degeneration can cause vision loss if left untreated and is one of the leading causes of visual impairment in the world. Most treatments are based on intravitreally injected therapeutics that inhibit the action of vascular endothelial growth factor. However, due to the need for monthly injections, this method is associated with poor patient compliance. To address this problem, numerous drug delivery systems (DDSs) have been developed. This review covers a selection of particulate systems, non-stimuli responsive hydrogels, implants, and composite systems that have been developed in the last few decades. Depending on the type of DDS, polymer material, and preparation method, different mechanical properties and drug release profiles can be achieved. Furthermore, DDS development can be optimized by implementing mathematical modeling of both drug release and pharmacokinetic aspects. Several existing mathematical models for diffusion-controlled, swelling-controlled, and erosion-controlled drug delivery from polymeric systems are summarized. Compartmental and physiologically based models for ocular drug transport and pharmacokinetics that have studied drug concentration profiles after intravitreal delivery or release from a DDS are also reviewed. The coupling of drug release models with ocular pharmacokinetic models can lead to obtaining much more efficient DDSs for the treatment of age-related macular degeneration and other diseases of the posterior segment of the eye.
几种慢性眼病会影响眼睛的后节。其中,年龄相关性黄斑变性(AMD)如果不治疗可能会导致视力丧失,是世界上导致视力损害的主要原因之一。大多数治疗方法都基于玻璃体内注射治疗药物,这些药物可以抑制血管内皮生长因子的作用。然而,由于需要每月注射一次,这种方法与患者的依从性较差有关。为了解决这个问题,已经开发了许多药物输送系统(DDS)。本篇综述涵盖了过去几十年中开发的一些颗粒系统、非刺激响应水凝胶、植入物和复合系统。根据 DDS 的类型、聚合物材料和制备方法,可以实现不同的机械性能和药物释放曲线。此外,通过对药物释放和药代动力学方面进行数学建模,可以对 DDS 开发进行优化。本文总结了几种用于扩散控制、溶胀控制和侵蚀控制的从聚合物系统中释放药物的现有数学模型。还综述了用于研究玻璃体内给药或 DDS 释放后眼部药物转运和药代动力学的药代动力学的房室模型和基于生理的模型。将药物释放模型与眼部药代动力学模型相结合,可以为治疗年龄相关性黄斑变性和其他后节眼病开发出更有效的 DDS。